Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab
Evelyn Yao, Klaus P. Hoeflich(Pivot), Marcia Belvin(CytomX Therapeutics (United States)), Nicholas Lewin‐Koh, Peter M. Haverty, Lesley Murray(Leeds Teaching Hospitals NHS Trust), Si Tuen Lee-Hoeflich(Bristol-Myers Squibb (United States)), Lori S. Friedman, Wei Zhou(Broad Institute), Bert Gunter, Tom Truong, Mark X. Sliwkowski(Molecular Oncology (United States)), Jeffrey Eastham‐Anderson
Cited by 124
Related Papers
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
|Nature Biotechnology|2008|1.4k
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
|Nature Biotechnology|2012|997
<b>Endocytosis and Sorting of ErbB2 and the Site of Action of Cancer Therapeutics Trastuzumab and Geldanamycin</b>
|Molecular Biology of the Cell|2004|489